Partner portal 
19001717 The HCC Risk test panel is an effective liver cancer screening method that combines three tumor markers: AFP, AFP-L3, and PIVKA-II. AFP is a protein produced by the fetal liver that can be elevated in liver cancer, but also in other benign liver conditions. AFP-L3 is a specific type of AFP more closely associated with liver cancer, helping to differentiate cancer from benign diseases. PIVKA-II is an incomplete blood clotting protein produced by liver cancer cells that has high sensitivity in detecting early-stage liver cancer, especially in people with chronic hepatitis B or C. Combining these three markers increases the ability to detect liver cancer early, stratify risk, and monitor treatment effectiveness. However, this test panel is only a screening tool, not a replacement for imaging diagnosis, and should be evaluated by a specialist in conjunction with other tests to reach a definitive conclusion.
